Public Notifications

Search

Search Results

Search Again
Soo Chan, Geoffrey Kyle (Dec 3, 2024)
  1. Nature of Action: The Inquiry Committee of the College of Pharmacists of British Columbia (“CPBC”) conducted investigations into the practice of Geoffrey Kyle Soo Chan (the “Registrant”), pursuant to section 33 (1) and (4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”). The CPBC issued a Citation on December 7, 2023.

Further to a proposal for resolution from the Registrant, the Inquiry Committee made a Consent Order under section 37.1 of the HPA.

  1. Effective date: December 3, 2024
  2. Name of registrant: Geoffrey Kyle Soo Chan
  3. Location of Practice: Vancouver, BC
  4. Admissions and Acknowledgments:

The Registrant has admitted and/or acknowledged the following:

The Registrant was the indirect owner and manager of Pharmachoice Main, located at 3882 Main Street in Vancouver (the “Pharmacy”).

Between January 1 and August 31, 2021, the Registrant processed approximately1646 transactions involving 28,404 doses of naloxone nasal spray using the personal health information and PharmaNet records of 301 patients who resided in various communities across BC (the “Transactions”).

For each of the Transactions, the Registrant did not dispense the doses of naloxone nasal spray to the patient whose personal health information and PharmaNet record he used. Instead, the Registrant dispensed the doses to the same individual who, in each case, purported to act in the capacity of patient representative for the patient.

For each of the Transactions, the Registrant

  1. processed and dispensed the nasal naloxone spray without obtaining patient consent as required by Standard 2(f) of the Code of Ethics – Detailed (the “Code of Ethics”) which is found in Schedule A of the Health Professions Act – BYLAWS (the “HPA Bylaws”),
  2. failed to take reasonable steps to confirm the identity of a patient or patient representative prior to providing a pharmacy service that requires accessing, using, or disclosing of patient personal health information, contrary to section 25.94 of the HPA, Section 36 of the Pharmacy Operations and Drug Scheduling Act – BYLAWS (the “PODSA Bylaws”) and Professional Practice Policy – 54: Identifying Patients and Patient Representatives in Community Pharmacy and Telepharmacy Settings,
  3. failed to protect and promote the health and well-being of the patient, exercise his professional judgment in furtherance of the best interests of the patient, and support the patient in making informed choices about care by explaining the benefits and risks associated with naloxone nasal spray, contrary to Standards 1(a), 2(a), and 2(b) of the Code of Ethics,
  4. failed, contrary to sections 66 and 67 of the HPA Bylaws,

(i)       to only collect personal health information from the patient or a person the patient authorized to be a source for the collection of the patient’s personal health information, and

(ii)      when collecting the patient’s personal health information from a person other than the patient, to take reasonable steps to ensure the patient was aware the patient’s personal health information was being collected, and the purpose for that collection,

  1. failed to keep the patient’s PharmaNet records current, contrary to section 35(1) of the PODSA Bylaws,
  2. failed to establish and maintain policies and procedures at the Pharmacy aimed at ensuring compliance with legislative requirements identified in subparagraphs (a) to (e), contrary to section 24(1)(a) of the PODSA Bylaws, and
  3. failed to avoid a situation that presented a conflict of interest and reduced the Registrant’s ability to be objective and unbiased in his professional judgment, contrary to Standard 8(d) of the Code of Ethics, as well as the Conflict of Interest Standards found in Schedule A of the HPA Bylaws.

Additionally, in the course of the investigation of the matters described in paragraphs 2 to 4, the Registrant submitted to the CPBC two copies of a July 7, 2021 prescription for naloxone nasal spray, the first on August 5, 2021 and the second on September 30, 2021. The copy of the prescription that was submitted on September 30, 2021 had been altered to indicate the Registrant had consulted with the person to whom the prescription was dispensed.

The described conduct of the Registrant constituted professional misconduct under the HPA.

  1. Disposition:

In the Consent Order under section 37.1 of the HPA, the Inquiry Committee ordered that the Registrant

  1. sign and deliver to the CPBC a letter of undertaking,
  2. be suspended for 6 months, commencing on an agreed date,
  3. for 3 years following the completion of the suspension, not act as, or apply to become

i.        a pharmacy manager,

ii.        a preceptor or supervisor for registered pharmacy students or international pharmacy graduates, or

iii.       an owner (indirect or direct) of an alternate pharmacy,

  1. after the end of that 3 years, and before applying to act as a pharmacy manager,

i.        successfully complete the BC Community Pharmacy Manager Training Program provided by the British Columbia Pharmacy Association, and

ii.        ensure that the policy and procedure manual for any pharmacy where he intends to act as a pharmacy manager includes sections addressing, (1) Patient Identification and Obtaining Informed Consent, (2) Authorization of Patient Agent/Representative, and (3) Dispensing of Nasal Naloxone Spray for Patients,

  1. thoroughly review and understand

i.        Part 1 of the Standards of Practice found in Schedule F of the HPA Bylaws,

ii.        section 67(1) of the HPA Bylaws,

iii.       the PODSA Bylaws, and

iv.       Professional Practice Policy – 54: Identifying Patients and Patient Representatives in Community Pharmacy and Telepharmacy Settings,

  1. successfully complete, as his own expense,

i.        the online “Decision Making and Documentation Keeping it Simple”, Part 1 & Part 2 modules offered as by part of the Optimizing Patient Care program by the Ontario College of Pharmacists,

ii.        the online module “Documentation in the World Expanded Scope”, provided as part of the Optimizing Patient Care Series by the Ontario College of Pharmacists,

iii.       the online “A Practical Approach to Patient Assessment (UofT)”, offered as part of the Optimizing Patient Care program by the Ontario College of Pharmacists,

iv.       the online module “Cultural Safety: Respect and Dignity in Relationships: Indigenous Peoples and the Health Care System”, provided as part of the Cultural Safety and Humility Action Series offered by the First Nations Health Authority, and

v.       the online module “Responding to Anti-Indigenous Racism in the Health Care System”, provided as part of the Cultural Safety and Humility Action Series offered by the First Nations Health Authority,

  1. read

i.        the article from Canadian Pharmacists Letter: HIPAA Privacy 2021, Volume 2021, Self-Study Course #21-301, and

ii.        the article from Canadian Pharmacists Letter: Naloxone’s Role in Opioid Overdose, Volume 2021, Self-Study Course #21-218,

  1. submit to the CPBC a written statement describing his learnings from completing the listed coursework and readings, including what changes he will make to his practice to prevent the recurrence of the conduct underlying the Consent Order, and how those changes will improve his practice going forward,
  2. at his own cost, write and successfully pass the CPBC’s Jurisprudence Exam,
  3. at his own cost, successfully complete and unconditionally pass, the PROBE Canada program on Professional/Problem Based Ethics,
  4. pay a fine of $20,000, and
  5. receive a letter or reprimand.

The Registrant repeatedly contravened sections of the HPA Bylaws, the PODSA Bylaws, and the Code of Ethics in his practice as a pharmacist, and as the pharmacy manager of the Pharmacy, and thereby, neglected his basic duties as a pharmacist, and demonstrated a disregard for the fundamentals of pharmacy practice.

The Registrant’s conduct is considered significant professional misconduct as defined in s. 26 of the HPA and justifies serious consequences. The Inquiry Committee therefore considered it appropriate, and the Registrant agreed, that the disposition for such conduct be one that serves as a strong deterrent and sends a clear message to both the profession and the public that the CPBC cannot and will not tolerate this type of conduct under any circumstances.

Pharmacist Registrant 57 (Nov 21, 2024)

The Inquiry Committee has removed all limits and conditions placed on the pharmacist registrant’s registration. The pharmacist registrant’s name has been withheld pursuant to s. 39.3(4) of the Health Professions Act.

Sidhu, Jaspaul Singh (Sep 24, 2024)

On September 24, 2024, the Panel of the Discipline Committee made the following orders of penalty:

  1. Pursuant to s. 20(4) of the Pharmacy Operations and Drug Scheduling Act, Jaspaul Singh Sidhu is prohibited from being an indirect or direct owner of a pharmacy in British Columbia until such time as he has fully complied with the College investigator’s December 2020 request for information.
     
  2. Pursuant to s. 20(1)(a) of the Pharmacy Operations and Drug Scheduling Act and s. 39(2) of the Health Professions Act, Jaspaul Singh Sidhu is ordered to pay a fine in the amount of $10,000.
     
  3. Pursuant to s. 20(1)(a) of the Pharmacy Operations and Drug Scheduling Act, s. 39(5) of the Health Professions Act and Schedule E of the Health Professions Act Bylaws, Jaspaul Singh Sidhu is ordered to pay the College’s costs and disbursements in the sum of $34,465.10.

December 14, 2023

On December 14, 2023, a Panel of the Discipline Committee, pursuant to section 39(1)(a) of the Health Professions Act, found that former shareholder indirect owner Jaspaul Singh Sidhu, of Surrey, British Columbia, failed to comply with his obligation to cooperate as a shareholder indirect owner under section 18(8) of the Pharmacy Operations and Drug Scheduling Act Bylaws.

 

Pharmacist Registrant 58 (Sep 9, 2024)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective September 6, 2024. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.

Pharmacist Registrant 6 (Aug 29, 2024)

The Inquiry Committee, pursuant to section 32.3(3)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective August 29, 2024. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


September 13, 2021
(AUgust 29, 2024 - Registration suspended)

The Inquiry Committee has approved to change pharmacist’s registration back to Active status after it had previously been suspended for an indefinite period on April 18, 2021. Pursuant to section 36(1) of the Health Professions Act, the Inquiry Committee has reached an Agreement with the pharmacist registrant whereby the pharmacist registrant consented to terms including, but not limited to, the following:

  1. To comply with any and all treatment plans as recommended by their medical providers;
     
  2. To comply with any and all return to work plans as advised by their medical providers and/or employers;
     
  3. To voluntarily stop working as a pharmacist and self-report to the College in the event that their medical condition may hinder their performance and/or fitness to practice as a pharmacist;
     
  4. To authorize and direct any and all caregivers, treating physicians, and/or institution(s) to furnish the College with a written report and any and all information that relates to their health, including a diagnosis, prognosis, status of recovery and/or treatment plan pertaining to their health condition and recovery, when and if necessary for the College to obtain such information;
     
  5. The College may furnish their treating physician(s) and any practitioner involved in their care with any information and documentation necessary for an independent medical assessment as well as monitoring and/or follow-up therapy, as necessary.

The pharmacist registrant’s name has been withheld pursuant to section 39.3(4) and (6) of the Health Professions Act.


December 8, 2020
(August 9, 2021 - Registration Reinstated)

The Inquiry Committee, pursuant to section 32.3(3)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective December 8, 2020. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


April 18, 2021
(September 13, 2021 - Registration Resinstated)

The Inquiry Committee, pursuant to section 32.2(4)(b)(ii) of the Health Professions Act, has reached an Agreement with the pharmacist registrant to voluntarily suspend their registration as a pharmacist effective April 18, 2021. The Agreement remains in effect until further notice. The Inquiry Committee considers the Agreement necessary to protect the public. The pharmacist registrant’s name has been withheld pursuant to section 39.3(4)(a) of the Health Professions Act.


February 20, 2015
(April 18, 2021 - Registration suspended)

Pharmacist Registrant 6 has satisfied the terms of an agreement reached with the Inquiry Committee dated October 3, 2010. Limits and conditions on pharmacist registrant’s registration as a pharmacist have now been removed. The pharmacist registrant’s name has been withheld pursuant to 39.3(4) of the Health Professions Act.


October 3, 2010
(February 20, 2015 - Limits and conditions removed)

The Inquiry Committee, pursuant to Section 36 of the Health Professions Act, has reached an agreement with pharmacist registrant to place limits and/or conditions on his registration as a pharmacist effective October 3, 2010. The agreement remains in effect until further notice. The Inquiry Committee considers the agreement necessary to protect the public. The pharmacist registrant's name has been withheld pursuant to 39.3(4) of the Health Professions Act

Tendo, Patience Akeh (Aug 26, 2024)
  1. Nature of Action: 

    The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted investigations into the conduct of Patience Akeh Tendo (the “Registrant”), pursuant to section 33(1) and 33(4) of the Health Professions Act RSBC 1996 c 183 (the “HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigations by way of a Consent Agreement pursuant to section 36(1) of the HPA.

  2. Effective date: August 26, 2024

  3. Name of registrant: Patience Akeh Tendo

  4. Location of Practice: Surrey, BC

  5. Admissions and Acknowledgments:

    The Registrant admitted and/or acknowledged that while practicing as a pharmacist and acting as indirect owner, director and pharmacy manager at a pharmacy, she:
    1. Allowed the pharmacy to be operated by non-pharmacists for two or three days without pharmacist supervision. This enabled non-pharmacists to process and dispense medications, including narcotic medications, using the Registrant’s registration number on PharmaNet;

    2. Failed to appoint a new manager to take her place prior to taking a leave of absence;

    3. Failed to submit a Change of Manager application to the College, thereby failing to inform the College of a change of pharmacy manager; and

    4. Allowed the pharmacy to operate without a manager.
       
  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that included (but are not limited to) the following:

    1. To thoroughly review and read legislation, standards, and policies relevant to the conduct to which this matter relates;

    2. To complete learning activities;

    3. To write and successfully pass the College’s Jurisprudence Exam;

    4. To not act as a pharmacy manager for a period of three years from August 26, 2024 to August 25, 2027;
       
    5. To not be an indirect owner, shareholder, officer, director, or direct owner of any pharmacy in BC for a period of three (3) years from August 26, 2024 to August 25, 2027; and

    6. To have a letter of reprimand placed on the College register for a period of three (3) years. 

  7. Rationale:

    The Inquiry Committee considered the Registrant’s conduct to be highly concerning and that it put patients and the public at increased risk of harm. They perceived that she lacked awareness of her legislative responsibilities as a pharmacist, manager and director. Further, they determined that the Registrant’s unawareness of her roles and responsibilities as manager and director were highly unprofessional.

    The Inquiry Committee ultimately concluded that the Registrant’s conduct was serious and in need of both remediation and deterrence in order to prevent similar recurrences in the future, to protect the public, and to uphold confidence in the integrity of pharmacy practice.

Sharma, Sahil (Aug 23, 2024)

Description of Action:

A panel of the Inquiry Committee (the “Panel”) of the College of Pharmacists of British Columbia (the “College”) has ordered that, effective August 23, 2024, the registration of pharmacist Sahil Sharma (the “Registrant”) is suspended pending completion of an investigation and any resulting disciplinary proceeding.

While his registration is suspended, the Registrant must not practice pharmacy in British Columbia, must not act as a pharmacy manager, and must not hold himself out as being a registrant of the College.

This interim suspension order is made pursuant to the authority for taking extraordinary action under section 35 of the Health Professions Act. Suspension under this authority requires the Inquiry Committee to be satisfied that the evidence shows there is a real risk of harm to patients, pharmacy professionals or other members of the public if the order is not made. However, it is important to note that the Inquiry Committee has not made any findings of fact or any findings as to whether any allegations regarding the Registrant are or are not proven.

Reasons for Action: 

The Registrant is the pharmacy manager of Lougheed Pharmacy (the “Pharmacy”), located at Unit 6 – 22932 Lougheed Hwy in Maple Ridge, BC.

The College received concerns from a member of the public regarding the Registrant and the Pharmacy, including their provision of Opioid Agonist Treatment (“OAT”) services. In May 2024, College inspectors performed an onsite inspection of the Pharmacy and identified what appeared to be multiple breaches of provincial legislation and College practice standards.

Based on the information before it, the Panel concluded that the Registrant’s continued practice of pharmacy and management of the Pharmacy poses significant risks to individual patients and the public. Under the Registrant’s management of the Pharmacy, allegations have been identified regarding the following matters:

  • Inadequate security and storage of narcotic inventory: Narcotic and controlled drugs were not appropriately secured and stored both inside and outside of the Pharmacy.
  • Inadequate protection of personal information: Patient information was not appropriately secured both inside and outside of the Pharmacy.
  • Inadequate management of narcotic inventory: Inventory management procedures and related records for narcotic and controlled drugs were not appropriately maintained.
  • Inadequate prescription labelling: Prepared prescription products, including narcotic and controlled drugs, were found to be improperly, inaccurately, or completely unlabelled.
  • Inadequate final checks: Prepared prescription products, including narcotic and controlled drugs, were found to have contents differing from the prescription label and the prescriber’s original prescription.
  • Inadequate record keeping: Prescription and dispensing records were incomplete and inconsistent.
  • Inadequate security measures: The Pharmacy’s security equipment did not meet legislated requirements.

The Panel also considered the Registrant had been previously investigated for similar concerns at a different pharmacy in 2019. The Panel noted that, as a result of that previous investigation, the Registrant had declared his remediation of the concerns identified at that time and his understanding of legislated requirements and had given undertakings to abide by those requirements in future. It appeared to the Panel that the Registrant did not comply with these legislated requirements, and instead consciously placed his own interests ahead of diligently adhering to requirements and protecting his patients from potential harm.

The Panel considered what interim measures would be sufficient and proportionate in this case. Due to the Registrant’s questionable judgment over an extended period of time and his pattern of repeated non-compliance with legislated requirements, the Panel was not satisfied that the Registrant would comply with any limits or conditions that would satisfactorily protect the public. Therefore, having weighed the available options and circumstances of the case, and having considered the impact on the Registrant, the Panel concluded that protection of the public can only be achieved through an interim suspension of the Registrant’s registration.

Lougheed Pharmacy (Aug 23, 2024)

Description of Action:

A panel of the Inquiry Committee (the “Panel”) of the College of Pharmacists of British Columbia (the “College”) has ordered that, effective August 23, 2024, there be limits and conditions placed on the pharmacy licence of Lougheed Pharmacy (the “Pharmacy”) located at Unit 6 – 22932 Lougheed Hwy in the city of Maple Ridge, pending completion of an investigation and any resulting disciplinary proceeding.

The limits and conditions include 1) that the manager of the pharmacy shall not be pharmacist Sahil Sharma; 2) that any manager shall be an individual in good standing with the College with management qualifications and experience; and 3) that any manager of the Pharmacy shall be approved by the College.

This interim order is made pursuant to the authority for taking extraordinary action under section 35 of the Health Professions Act and section 20 of the Pharmacy Operations and Drug Scheduling Act. Interim action under this authority requires the Inquiry Committee to be satisfied that the evidence shows there is a real risk of harm to patients, pharmacy professionals or other members of the public if the order is not made. However, it is important to note that the Inquiry Committee has not made any findings of fact or any findings as to whether any allegations regarding the Pharmacy are or are not proven.

Reasons for Action:

The Pharmacy’s manager is pharmacist Sahil Sharma (the “Registrant”). The Registrant is also the indirect owner of the Pharmacy. Effective August 23, 2024, the Registrant’s registration is suspended pending completion of an investigation and any resulting disciplinary proceeding.

The College received concerns from a member of the public regarding the Registrant and the Pharmacy, including their provision of Opioid Agonist Treatment (“OAT”) services. In May 2024, College inspectors performed an onsite inspection of the Pharmacy and identified what appeared to be multiple breaches of provincial legislation and College practice standards.

Based on the information before it, the Panel concluded that the Pharmacy’s continued operation under the Registrant’s management poses significant risks to individual patients and the public. Under the Registrant’s management of the Pharmacy, allegations have been identified regarding the following matters:

  • Inadequate security and storage of narcotic inventory: Narcotic and controlled drugs were not appropriately secured and stored both inside and outside of the Pharmacy.
  • Inadequate protection of personal information: Patient information was not appropriately secured both inside and outside of the Pharmacy.
  • Inadequate management of narcotic inventory: Inventory management procedures and related records for narcotic and controlled drugs were not appropriately maintained. 
  • Inadequate prescription labelling: Prepared prescription products, including narcotic and controlled drugs, were found to be improperly, inaccurately, or completely unlabelled.
  • Inadequate final checks: Prepared prescription products, including narcotic and controlled drugs, were found to have contents differing from the prescription label and the prescriber’s original prescription.
  • Inadequate record keeping: Prescription and dispensing records were incomplete and inconsistent.
  • Inadequate security measures: The Pharmacy’s security equipment did not meet legislated requirements.

The Panel also considered the Registrant had been previously investigated for similar concerns at a different pharmacy in 2019. The Panel noted that, as a result of that previous investigation, the Registrant had declared his remediation of the concerns identified at that time and his understanding of legislated requirements and had given undertakings to abide by those requirements in future. It appeared to the Panel that the Registrant did not comply with these legislated requirements, and instead consciously placed his own interests ahead of diligently adhering to requirements and protecting his patients from potential harm.

The Panel considered what interim measures would be sufficient and proportionate in this case. After having weighed the different options and circumstances of the case, and having considered the impact on the Pharmacy’s operations, the Panel concluded that limits and conditions on who can act as the Pharmacy’s manager, without clinical involvement of the Registrant, were necessary to protect the public.

Elbably, Sameh (Aug 12, 2024)
  1. Nature of Action: 

    The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the conduct of Sameh Elbably (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: August 12, 2024

  3. Name of registrant: Sameh Elbably

  4. Location of Practice: Kelowna, BC

  5. Admissions and Acknowledgments:

    The Inquiry Committee determined, and the Registrant acknowledged that he:
    1. Dispensed nineteen (19) prescriptions without valid authorization and despite having a “reversed” status on PharmaNet, for himself and members of his family, contrary to section 19(5) and 35(1) of the Pharmacy Operations and Drug Schedule Act Bylaws and section 11(1) of the HPA Bylaws, Schedule F, Part I – Community Pharmacy Standards of Practice;

    2. Practiced outside his scope of pharmacy practice when he dispensed and provided unauthorized prescriptions for himself and his family members, contrary to standard 1 and standard 7 of the HPA, Bylaws, Schedule A, Code of Ethics – Detailed (“Code of Ethics”)

    3. Dispensed medications to himself and his family members, contrary to standard 2 of the HPA Bylaws, Schedule A – Code of Ethics, Conflict of Interest Standards and standard 8 of the Code of Ethics;

    4. Contrary to standard 9 of the Code of Ethics, attempted to conceal his conduct by reversing nineteen (19) prescriptions on PharmaNet, despite dispensing them, which included falsifying four (4) verbal order prescriptions. He also provided disingenuous information to the College Investigator; and
       
    5. Dispensed six (6) inappropriate emergency supply prescriptions for his spouse by failing to adhere to Professional Practice Policy 31 – Emergency Supply for Continuity of Care.
       
  6. Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that included (but not limited to) the following:

    1. To thoroughly review and read legislation, standards, and policies relevant to the conduct which this matter relates, and thereafter to submit a Declaration of Understanding to the College;

    2. To complete learning activities

    3. To review and complete the Code of Ethics: Educational Tutorial by the College;

    4. To complete and successfully pass an ethics course for healthcare professionals within 180 days of signing the Agreement;
       
    5. To appear before the Inquiry Committee for a verbal reprimand after completing the ethics course;

    6. To pay a $2,000 fine;

    7. To have a letter of reprimand placed on the College register for a period of three (3) years;

    8. To be suspended as a registrant of the College for a period of ninety (90) days from August 12, 2024 to November 9, 2024; and

    9. To not act as a pharmacy manager or a preceptor of pharmacy students and/or international pharmacy graduates for a period of three (3) years following the completion of his suspension 

  7. Rationale:

    The Inquiry Committee considered the Registrant’s conduct demonstrated a severe and prolonged pattern of behavior. They also considered the Registrant’s lack of understanding regarding the gravity of his conduct as well as the Registrant’s lack of accountability to professional practice standards.

    The Inquiry Committee believed the Registrant’s explanations and justifications for his conduct were not valid. They also perceived the Registrant’s decision-making to be lacking and judged the breadth and scope of his conduct as indicative of poor judgement. Furthermore, the Inquiry Committee deemed the Registrant’s unethical conduct, which included falsifying prescription documentation as well as an apparent intent to mislead colleagues and the College, to be extremely concerning.

    Therefore, the Inquiry Committee considered that the appropriate disposition regarding the Registrant’s conduct include significant remediation and serious punitive measures. The Inquiry Committee considered the terms of the Consent Agreement necessary to protect the public, uphold confidence in the integrity of pharmacy practice, and to send a clear message of deterrence to the profession.

Ip, Kenny Albert Gregory (Aug 8, 2024)
  1. Nature of Action: 

    The Inquiry Committee of the College of Pharmacists of British Columbia (the “College”) conducted an investigation into the practice of Kenny Ip (the “Registrant”), pursuant to section 33(4) of the Health Professions Act, R.S.B.C. 1996, c. 183 (“HPA”).

    The Inquiry Committee and the Registrant have agreed to resolve all matters arising from the investigation by way of a Consent Agreement under section 36(1) of the HPA.

  2. Effective date: August 8, 2024 

  3. Name of registrant: Kenny Albert Gregory Ip

  4. Location of Practice: Vancouver, BC

  5. Admissions and Acknowledgments:

    The Inquiry Committee determined, and the Registrant has acknowledged, that while practicing as a pharmacist and pharmacy manager at a pharmacy, he:
    1. Operated the pharmacy without a valid pharmacy license contrary to section 7 of Pharmacy Operations and Drug Scheduling Act, S.B.C. 2003, c. 77 (“PODSA”) and section 18(2) of the PODSA Bylaws.

    2. Reported that he was unaware that the pharmacy’s licence had expired despite repeated reminders from the College’s Registration and Licensure department. The Registrant was not knowledgeable of and did not adhere to legislation and standards of practice contrary to standard 1(d) and 7(d) of HPA Bylaws, Schedule A, Code of Ethics, Code of Ethics – Detailed.

    3. Did not complete and declare his pharmacy manager training every three years contrary to Professional Practice Policy 69 – Community Pharmacy Manager Education.

    Disposition:

    The Registrant entered into a Consent Agreement with the College’s Inquiry Committee, wherein the Registrant consented to terms that included (but are not limited to) the following:

    1. To not act as a pharmacy manager for a period of sixty (60) days from August 8, 2024 to October 6, 2024;

    2. To have a letter of reprimand placed permanently on the College register;

    3. To pay a $5,000 fine; and

    4. To complete and successfully pass an ethics course for healthcare professionals within 180 days of signing the Agreement.
       
  6. Rationale:

    The Inquiry Committee considered that the Registrant, with his years of experience of being a pharmacy manager, should have been familiar with the licence renewal process. Despite multiple reminders from the College regarding the pharmacy’s licence expiring, the Registrant operated the pharmacy without a valid pharmacy licence. The Registrant also did not complete and declare his pharmacy manager training every three years.

    The Inquiry Committee ultimately concluded that the Registrant was not knowledgeable of and did not adhere to legislation. Therefore, the Inquiry Committee considered the Registrant’s conduct to be serious, and that the Registrant required both remediation and deterrence in order to come into compliance.

Pages